Conversion treatment for advanced intrahepatic cholangiocarcinoma:Opportunities and challenges  

作　　者：Jun-Jie Liu Mi Zhou Tong Yuan Zhi-Yong Huang Zun-Yi Zhang 

机构地区：[1]Hepatic Surgery Center,Tongji Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430030,Hubei Province,China

出　　处：《World Journal of Gastroenterology》2025年第15期24-41,共18页世界胃肠病学杂志(英文)

摘　　要：The prevalence of intrahepatic cholangiocarcinoma(ICC)is increasing globally.Despite advancements in comprehending this intricate malignancy and formulating novel therapeutic approaches over the past few decades,the prognosis for ICC remains poor.Owing to the high degree of malignancy and insidious onset of ICC,numerous cases are detected at intermediate or advanced stages of the disease,hence eliminating the chance for surgical intervention.Moreover,because of the highly invasive characteristics of ICC,recurrence and metastasis postresection are prevalent,leading to a 5-year survival rate of only 20%-35%following surgery.In the past decade,different methods of treatment have been investigated,including transarterial chemoembolization,transarterial radioembolization,radiotherapy,systemic therapy,and combination therapies.For certain patients with advanced ICC,conversion treatment may be utilized to facilitate surgical resection and manage disease progression.This review summarizes the definition of downstaging conversion treatment and presents the clinical experience and evidence concerning conversion treatment for advanced ICC.

关 键 词：Intrahepatic cholangiocarcinoma Conversion treatment DOWNSTAGING Combination therapy Chemotherapy IMMUNOTHERAPY Locoregional therapies 

分 类 号：R735.7[医药卫生—肿瘤]